线粒体代谢影响年轻与高龄产妇女性人类卵母细胞的减数分裂成熟
本研究纳入年轻(≤34岁)和高龄(>37岁)女性的340个生发泡(GV)卵母细胞,体外成熟30小时后评估线粒体分布与功能。高龄卵母细胞线粒体活性更低(D-LAT强度12517±10187 AU vs 年轻78614±58534 AU,P=0.003),代谢动态成像显示高龄卵母细胞减数分裂成熟率更低(62.3% vs 86.3%,P=0.002),提示线粒体代谢受损影响减数分裂进程。
要点
- 高龄女性GV卵母细胞的线粒体活性显著低于年轻女性。
- 年轻女性GV卵母细胞减数分裂时代谢平均增加4%,高龄者几乎不增加。
- 高龄卵母细胞体外成熟至MII阶段的比例显著低于年轻卵母细胞。
核心结论
- 线粒体代谢不良会损害人类GV卵母细胞的减数分裂进程,导致高龄女性卵母细胞成熟能力下降。
研究设计与样本
- 研究纳入年轻(≤34岁)和高龄(>37岁)女性的340个GV卵母细胞,体外成熟30小时。
- 80个卵母细胞用于线粒体蛋白免疫荧光成像,171个用于活细胞成像,89个用于功能缺失分析(年轻GV卵母细胞用1 μM FCCP处理30分钟)。
主要发现
- 高龄卵母细胞线粒体活性D-LAT强度为12517±10187 AU,低于年轻卵母细胞的78614±58534 AU(P=0.003)。
- 高龄卵母细胞TOMM20强度为32186±33414 AU,低于年轻卵母细胞的61674±24322 AU,但差异未达统计学显著(P=0.195)。
- FLIM氧化还原比值高龄组为1e+00±0.16,低于年轻组的2e+00±0.15(P=2.969e-05)。
- 年轻女性GV卵母细胞在生发泡破裂后代谢平均增加4%,高龄卵母细胞几乎无增加且变异性更高。
- 高龄卵母细胞成熟至MII阶段的比例为62.3%(38/61),低于年轻卵母细胞的86.3%(63/73)(P=0.002)。
局限性
- 成熟率仅通过第一极体排出评估,可能忽略纺锤体组装时间的变化。
- 功能缺失研究中线粒体活性的定量仅通过免疫荧光染色评估。
- 纳入的卵母细胞来自接受卵巢刺激的女性,可能无法忠实反映生理性成熟过程。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Is there a relationship between the mitochondrial activity and the meiotic progression of oocytes from germinal vesicle (GV) to metaphase II (MII) stages in young and advanced maternal age (AMA) women? SUMMARY ANSWER: Poor mitochondrial metabolism impairs the meiotic progression of human GV oocytes, contributing to a lower oocyte maturation capacity of AMA oocytes. WHAT IS KNOWN ALREADY: AMA oocytes are characterized by diminished quality, mostly due to the higher rates of chromosomal segregation errors occurring during meiosis I. Another hallmark of AMA oocytes is impaired mitochondrial metabolism. Studies in mice have suggested a link between metabolic dysfunction and meiotic failure, but this relationship has not been fully elucidated in humans. Metabolic dynamics can be visualized by indirect measurements through mitochondrial staining and quantified more directly using fluorescence lifetime imaging microscopy (FLIM). This live-imaging approach can generate metabolic timelapse profiles of oocytes throughout meiosis. In the present study, we explored mitochondrial distribution and functionality in human oocytes at the GV and MII stages, obtained from young and AMA women, to establish the role of mitochondrial metabolism in meiosis progression. STUDY DESIGN, SIZE, DURATION: A total of 340 GV oocytes from young (≤34 years) and AMA (>37 years) women were included in the study. Denuded GVs were matured in vitro in G2-plus medium for 30 h. Maturation was determined by the presence of the extruded first polar body (PB1). The collected oocytes were processed for mitochondrial protein imaging (n = 80), or for live imaging (n = 171). Moreover, 89 oocytes were used for loss-of-function analysis by treating young GVs with 1 μM trifluoromethoxy-carbonylcyanide-phenylhydrazone (FCCP) for 30 min before in vitro maturation. PARTICIPANTS/MATERIALS, SETTING, METHODS: The proteins dihydrolipoamide-S-acetyltransferase (D-LAT) and translocase-of-outer mitochondrial-membrane (TOMM20) were analyzed in young and AMA oocytes by immunofluorescence to assess mitochondrial activity and localization, respectively. Fluorescence mean intensities (arbitrary-unit, AU) were quantified with ImageJ and compared by t-test; maturation rates were compared by chi-squared test. FLIM comprehensive metabolism (NAD(P)H; FAD+) was taken at GV stage. Different FLIM parameters (fluorescence intensity, fraction bound, short/long lifetime) and the Redox ratio (NAD(P)H intensity/FAD+ intensity) were evaluated. MAIN RESULTS AND THE ROLE OF CHANCE: The findings revealed that active mitochondria are specifically localized in the subcortical area, while mitochondria in general are distributed across the whole oocyte. This pattern was substantially maintained in AMA oocytes, which were in turn characterized by a lower mitochondrial activity (D-LAT intensity of 78 614 ± 58 534 AU in young, 12 517 ± 10 187 AU in AMA, P = 0.003), while a lower number of mitochondria was observed In AMA patients but the difference did not reach statistical significance (TOMM20 intensity of 61 674 ± 24 322 AU in young, 32 186 ± 33 414 AU in AMA, P = 0.195). Using non-invasive FLIM, we assessed the metabolic dynamics of maturing oocytes (Redox ratio in young 2e + 00 ± 0.15, in AMA 1e + 00 ± 0.16, P = 2.969e-05), confirming a similar pattern observed by immunofluorescence. Specifically, FLIM microscopy revealed that GV oocytes from young women slightly increased their metabolism, by 4% on average, after the GV breakdown, and the increase was very consistent across different oocytes. On the contrary, in AMA maturing oocytes, little to no increase in metabolism was observed; they were characterized instead by higher variability, and more AMA oocytes failed to successfully reach the MII stage [AMA oocytes (62.3%; 38/61) compared with young oocytes (86.3%; 63/73; P = 0.002). These differential trends observed in AMA oocytes compared to the young oocytes suggest that impaired metabolic activity significantly compromises maturation capacity, revealing a functional link between adequate metabolic levels and successful meiosis progression. LIMITATIONS, REASONS FOR CAUTION: Maturation rates were assessed by the presence of an extruded PB1 and variations in spindle assembly timings may have been overlooked. The quantification of mitochondrial activity in loss-of-function studies was assessed only by immunofluorescence staining. Additionally, the oocytes included in the present study were collected from women who underwent ovarian stimulation and may not faithfully recapitulate physiological maturation. WIDER IMPLICATIONS OF THE FINDINGS: Our findings demonstrate the presence of a functional link between oocyte mitochondrial metabolism and meiosis progression, which may contribute to the decline of oocyte quality with aging. Overall, we provided evidence to understand the biological mechanisms in mitochondrial metabolism that might contribute to driving the decay in oocyte quality in AMA women. STUDY FUNDING/COMPETING INTEREST(S): This project received intramural funding from the Eugin Group and funding from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 860960. T.S. is a former owner and former stock owner of Optiva Fertility Inc (company closed) and filed two patents for Optiva Fertility Inc (both abandoned). D.S.: Presenter EMD Senoro and Dep. Editor of Human Reproduction. All of the other authors (S.P., M.M., M.B., E.I., M.P., R.V., and F.Z.) have no conflicts of interest to declare. All of the authors contributed substantially to the manuscript and approve its submission. TRIAL REGISTRATION NUMBER: N/A.
引用
- Pietroforte S, Martins M, Barragan M, et al. Mitochondrial metabolism influences meiotic maturation in human oocytes of young and advanced maternal age women. Hum Reprod. 2025. PMID: 41206610. doi:10.1093/humrep/deaf207
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。